Literature DB >> 21605070

Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.

Esther Raskopf1, Annabelle Vogt, Georges Decker, Sarah Hirt, Katjana Daskalow, Thorsten Cramer, Jens Standop, Maria-Angeles Gonzalez-Carmona, Tilman Sauerbruch, Volker Schmitz.   

Abstract

Control of VEGF signaling is an intense objective of pre-clinical and clinical studies in HCC disease with steadily increasing clinical application. Despite its emerging role, several aspects of anti-VEGF based treatments are poorly investigated, like the impact on tumor cells themselves, such as the effect on intracellular signaling and apoptosis induction in hepatoma cells. Effects of siRNA-VEGF on VEGF, VEGF-receptor expression and VEGF-A signaling such as AKT and JNK phosphorylation were determined under normoxic or hypoxic conditions in murine hepatoma cells. Apoptosis induction was analyzed by SubG1-fraction, JC1-staining and caspase-8 activation. VEGF receptor expression was analysed by semiquantitative real time PCR. Independent of oxygen status, siRNA-VEGF reduced VEGF levels resulting in decreased AKT and increased JNK phosphorylation in Hepa129 cells. The VEGF-receptors neuropilin-1 (Nrp1) and neuropilin-2 (Nrp2) were downregulated following siRNA-VEGF treatment or hypoxia induction respectively. Functionally, hypoxia significantly increased the apoptosis rate (as analyzed by SubG1-fraction, JC1-staining and JNKphosphorylation) which was further stimulated by siRNA-VEGF treatment. Our data indicate that antitumoral efficacy of an anti-VEGF based treatment with siRNA is partly based on negative autocrine feedback mechanisms which are even enhanced under hypoxic conditions. This observation helps to understand why antitumoral efficacy can be maintained despite of counteracting stimulation of tumoral VEGF secretion due to hypoxia. The direct impact on tumor cells further underscores the attractiveness of an anti-VEGF based siRNA treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21605070     DOI: 10.2174/138920112802502088

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  4 in total

Review 1.  Neuropilins and liver.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

2.  Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF.

Authors:  Qian Bi; Shanhong Tang; Lin Xia; Rui Du; Rui Fan; Liucun Gao; Jiang Jin; Shuhui Liang; Zheng Chen; Guanghui Xu; Yongzhan Nie; Kaichun Wu; Jie Liu; Yongquan Shi; Jie Ding; Daiming Fan
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 3.  SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.

Authors:  Elisabetta Valentini; Marta Di Martile; Donatella Del Bufalo; Simona D'Aguanno
Journal:  J Exp Clin Cancer Res       Date:  2021-04-15

4.  Toxic damage increases angiogenesis and metastasis in fibrotic livers via PECAM-1.

Authors:  Esther Raskopf; Maria Angeles Gonzalez Carmona; Christina Jay Van Cayzeele; Christian Strassburg; Tilman Sauerbruch; Volker Schmitz
Journal:  Biomed Res Int       Date:  2014-03-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.